Bright Competitors
| DRUG Stock | USD 39.49 0.74 1.91% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Bright Minds competition on your existing holdings.
The current Return On Tangible Assets is estimated to decrease to -0.55. The current Return On Capital Employed is estimated to decrease to -0.61. At this time, Bright Minds' Total Assets are most likely to increase significantly in the upcoming years. The Bright Minds' current Total Current Assets is estimated to increase to about 8.4 M, while Net Tangible Assets are projected to decrease to roughly 8.4 M. Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bright Minds' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Bright Minds Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Bright Minds and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Bright and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Bright Minds Biosciences does not affect the price movement of the other competitor.
| 0.32 | 0.24 | 0.09 | 0.58 | 0.58 | IPSC | ||
| 0.32 | -0.36 | 0.61 | 0.1 | -0.27 | EWTX | ||
| 0.24 | -0.36 | -0.56 | 0.59 | 0.55 | CCCC | ||
| 0.09 | 0.61 | -0.56 | -0.26 | -0.3 | MLYS | ||
| 0.58 | 0.1 | 0.59 | -0.26 | 0.61 | ERAS | ||
| 0.58 | -0.27 | 0.55 | -0.3 | 0.61 | NUVL | ||
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Bright Stock performing well and Bright Minds Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Bright Minds' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| IPSC | 3.19 | (0.15) | (0.03) | (0.01) | 3.30 | 9.09 | 21.88 | |||
| EWTX | 2.02 | (0.19) | 0.00 | (0.27) | 0.00 | 4.02 | 13.11 | |||
| CCCC | 5.54 | 0.81 | 0.18 | 0.59 | 4.40 | 12.50 | 34.73 | |||
| MLYS | 2.41 | (0.17) | 0.00 | (0.33) | 0.00 | 4.39 | 12.71 | |||
| ERAS | 3.85 | 0.34 | 0.07 | 0.42 | 4.38 | 7.14 | 40.64 | |||
| NUVL | 1.92 | 0.09 | 0.05 | 0.17 | 2.14 | 4.52 | 13.88 |
Cross Equities Net Income Analysis
Compare Bright Minds Biosciences and related stocks such as Century Therapeutics, Edgewise Therapeutics, and C4 Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPSC | (246 M) | (246 M) | (246 M) | (246 M) | (246 M) | (246 M) | (246 M) | (246 M) | (246 M) | (246 M) | (54.7 M) | (95.8 M) | (130.9 M) | (136.7 M) | (126.6 M) | (132.9 M) |
| EWTX | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (17.1 M) | (42.1 M) | (15.4 M) | (100.2 M) | (133.8 M) | (127.1 M) |
| CCCC | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (34.1 M) | (66.3 M) | (86 M) | (126.5 M) | (132.5 M) | (105.3 M) | (110.6 M) |
| MLYS | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (19.4 M) | (29.8 M) | (71.9 M) | (177.8 M) | (168.9 M) |
| ERAS | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (173.1 M) | (150.1 M) | (238.2 M) | (125 M) | (161.7 M) | (169.7 M) |
| NUVL | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (14.6 M) | (46.3 M) | (73.3 M) | (126.2 M) | (260.8 M) | (247.7 M) |
Bright Minds Biosciences and related stocks such as Century Therapeutics, Edgewise Therapeutics, and C4 Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Bright Minds Biosciences financial statement analysis. It represents the amount of money remaining after all of Bright Minds Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Bright Minds Competitive Analysis
The better you understand Bright Minds competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Bright Minds' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Bright Minds' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Bright Minds Competition Performance Charts
Five steps to successful analysis of Bright Minds Competition
Bright Minds' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Bright Minds Biosciences in relation to its competition. Bright Minds' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Bright Minds in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Bright Minds' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Bright Minds Biosciences, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Bright Minds position
In addition to having Bright Minds in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Convertibles Funds Thematic Idea Now
Convertibles Funds
Funds or Etfs that invest in debt that is expected to be converted into a predetermined amount of the company equity at some future date. The Convertibles Funds theme has 12 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Convertibles Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Bright Minds Correlation with its peers. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.